Table 3.
Association study of NCF1 rs201802880 and clinical characteristics of SLE and SSc (case-case analysis).
| Additive model for A allele | |||
|---|---|---|---|
| P | Q | OR (95%CI) | |
| SLE | |||
| onset < 20 years vs ≥ 20 years | 0.0033 | 0.0095 | 1.48 (1.14–1.93) |
| renal disorder present vs absent | 0.85 | 0.89 | 0.98 (0.80–1.20) |
| neurologic disorder present vs absent | 0.70 | 0.89 | 1.05 (0.81–1.36) |
| anti-dsDNA antibody present vs absent | 0.027 | 0.059 | 1.35 (1.04–1.77) |
| anti-Sm antibody present vs absent | 0.85 | 0.89 | 1.02 (0.82–1.27) |
| anti-RNP antibody present vs absent | 0.80 | 0.89 | 1.03 (0.81–1.31) |
| SSc | |||
| dcSSc vs lcSSc | 0.45 | 0.76 | 0.87 (0.59–1.25) |
| ATA present vs absent | 0.94 | 0.89 | 1.01 (0.68–1.49) |
| ACA present vs absent | 0.63 | 0.89 | 1.09 (0.77–1.54) |
| ILD present vs absent | 0.65 | 0.89 | 1.08 (0.77–1.52) |
Genotypes of rs201802880 in SLE and SSc patients with and without specific clinical characteristics were compared using logistic regression analysis under the additive model for A allele with adjustment for sex. Significant enrichment of A allele was observed among SLE patients with onset of <20 years as compared with onset of ≥20 years. FDR P values (Q) were calculated by Benjamini-Hochberg method
dcSSc: diffuse cutaneous SSc, lcSSc: limited cutaneous SSc, ATA: anti-topoisomerase I antibody, ACA: anti-centromere antibody, ILD: interstitial lung disease. Q: FDR P value.